FN2 Earnings Intelligence
Leidos Holdings, Inc. earnings overview
Latest Leidos Holdings, Inc. (LDOS) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Leidos Holdings, Inc.
The supplied Q2 analysis supports a constructive near-term operating thesis for Leidos: defense bookings, new program opportunities, and raised full-year guidance strengthen the growth case. That case is balanced by health-segment payment uncertainty, possible in-sourcing, government funding risk, and execution demands.
Leidos Holdings, Inc.
Leidos reported Q1 FY2026 revenue of $4.4B (up 4% YoY) and adjusted EBITDA margin of 14%, beating consensus on both lines. EPS of $3.13 exceeded the $2.90 estimate by 7.9%, and revenue of $4.4B topped the $4.28B estimate by 2.8%. Management raised full-year 2026 guidance for revenue, non-GAAP EPS, and operating cash flow, driven by the rapid two-month close of the Entrust acquisition and major contract wins including the AGM-190A missile and Seahawk MUSV programs. Despite the beat-and-raise, shares fell 8.6% on the report session with 2.5x normal volume and drifted an additional 9.4% lower subsequently. Investors focused on management's flagged Q2 revenue and margin trough, profitability pressure from fixed-price defense programs, and uncertainty around the $350M capex ramp. The stock now trades at $112.41, near the low end of analyst targets.
Leidos Holdings, Inc.
Leidos's raised guidance, strong book-to-bill and large contract pipeline support the case for resilient demand, but the thesis depends on converting that demand into growth and returns on a substantially larger 2026 investment program.
Leidos Holdings, Inc.
The supplied analysis supports a constructive but conditional view: Leidos is showing broad operating momentum through energy infrastructure, defense technology and health services, but the durability of that growth depends on government funding, award timing, contract retention and disciplined investment.
Leidos Holdings, Inc.
The current analysis supports a constructive operating thesis for Leidos: growth in maritime autonomy, AI-enabled productivity, managed health services and acquisition-driven capability expansion coincided with raised full-year guidance. The thesis is tempered by procurement timing, policy uncertainty and competitive risks.
Leidos Holdings, Inc.
The supplied analysis supports a constructive but conditional view: management sees resilient federal demand and multiple NorthStar 2030 growth avenues, while execution, federal-budget timing, contract reviews, and acquisition integration remain key tests.
Leidos Holdings, Inc.
The supplied analysis supports a constructive but conditional view: Leidos enters the next period with strong backlog, federal demand, and a multi-year growth plan, while budget timing and execution risks remain material.
Get the LDOS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.